RT journal article
T1 Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
A1 Pereyra-Rodríguez, José Juan
A1 Herranz, Pedro
A1 Ruiz-Villaverde, Ricardo
A1 Elosua-González, Marta
A1 Galán Gutiérrez, Manuel
A1 Figueras-Nart, Ignasi
A1 Miquel-Miquel, Javier
A1 de la Cueba Dobao, Pablo
A1 Serra-Baldrich, Esther
A1 Munera-Campos, Monica
A1 Melé-Ninot, Gemma
A1 Expósito-Serrano, Vicente
A1 Pérez, Bibiana
A1 Serrano, Amalia
A1 Ortiz de Frutos, Francisco Javier
A1 Armario Hita, José Carlos
A2 Cirugía
A2 Medicina
K1 atopic dermatitis
AB Background Tralokinumab was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) and is the first selective interleukin (IL)-13 inhibitor that specifically neutralizes IL-13 with high affinity.Objectives To determine the real-life short-term effectiveness and safety of tralokinumab treatment in patients with moderate-to-severe AD.Methods A multicentre retrospective study was conducted including adult patients with moderate-to-severe AD who started tralokinumab treatment from 1 April to 30 June 2022 in 16 Spanish hospitals. Demographic and disease characteristics, severity and quality of life scales were collected at the baseline visit and at weeks 4 and 16.Results Eighty-five patients were included. Twenty-seven patients (32%) were non-naive to advanced therapy (biological or Janus kinaseinhibitors inhibitors). All included patients had severe disease with baseline Eczema Area and Severity Index (EASI) scores of 25.4 (SD 8.1), Dermatology Life Quality Index (DLQI) 15.8 (5.4) and peak pruritus numerical rating scale  (PP-NRS) 8.1 (1.8) and 65% had an Investigator’s Global Assessment (IGA) of 4. At week 16, there was improvement on all scales. The mean EASI decreased to 7.5 (SD 6.9, 70% improvement), SCORing Atopic Dermatitis improved 64% and PP-NRS, 57%. Also, 82%, 58% and 21% of the patients achieved EASI 50, 75 and 90, respectively. The percentage of EASI 75 responders was significantly higher among the naive vs. non-naive groups (67% vs. 41%). The safetyprofile was acceptable.Conclusions Patients, with a long history of disease and prior multidrug failure, showed a good response to tralokinumab, confirming clinical trial results.
PB Oxford University Press
SN 1365-2230
YR 2023
FD 2023-09
LK http://hdl.handle.net/10498/39535
UL http://hdl.handle.net/10498/39535
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 05-nov-2026